More on URGN

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+71.4% Growth)
- Ratings (7.7 Score)

Upcoming Events

- Earnings (8/6/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

UroGen Pharma (NQ:URGN)
Delayed: 40.23 +0.23 (0.58%)
Prev. Close $40.00  
Open$39.81 
52 Wk High$ 
52 Wk Low$ 
Day High$41.88 
Day Low$39.50 
P/E N/A  
EPS$ 
Volume1,265,323 

Friends, Peers and Foes (?): ABBV, ARGX, ARWR, BBIO, CGON (more...)

Jul 16, 2026 06:54 AM UroGen Pharma (URGN) PT Raised to $50 at Oppenheimer
Jul 16, 2026 06:49 AM H.C. Wainwright Reiterates Buy Rating on UroGen Pharma (URGN)
Jul 15, 2026 08:00 AM UroGen receives U.S. patent notice covering bladder cancer treatment
Jul 15, 2026 08:00 AM UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103
Jul 10, 2026 02:20 PM Form 4 UroGen Pharma Ltd. For: Jul 09 Filed by: Schoenberg Mark
Jul 9, 2026 04:20 PM Form 144 UroGen Pharma Ltd. Filed by: Schoenberg Mark
Jul 9, 2026 06:49 AM H.C. Wainwright Reiterates Buy Rating on UroGen Pharma (URGN)
Jul 8, 2026 08:02 AM UroGen gets FDA IND clearance for bladder cancer virus therapy
Jul 8, 2026 08:00 AM UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
Jun 24, 2026 10:23 AM Form 4 UroGen Pharma Ltd. For: Jun 22 Filed by: Schoenberg Mark
View All Articles

Entities mentioned with URGN

View All Entities